- Sodium–Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice
Cardiovascular (CV) disease remains a leading cause of morbidity and mortality worldwide with heart failure increasing in prevalence. Despite the significant advances in therapies and prevention, mortality and morbidity are still high and quality of life poor. The opportunity for CV disease prevention in patients with T2DM has recently expanded with antihyperglycemic agents demonstrating significant reductions in the risk of major adverse cardiovascular events (MACE) including many trials with SGLT2 inhibitors showing that drugs in this class cause robust reductions in heart failure. Although the exact mechanisms of CV benefit remain uncertain, they appear to be unrelated to the direct glucose-lowering effects. These agents have triggered a shift beyond glucose control, to a broader strategy of comprehensive CV risk reduction.
This comprehensive review article aims to educate practicing cardiologists and related healthcare professionals of the latest developments in this field, and support better patient outcomes.
Terms & Conditions
Radcliffe Education requires contributors to our CME programmes to disclose any relevant financial relationships that have occurred within the past 12 months that could create a conflict of interest. These will be identified in the faculty section if applicable.
This review article, 'Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure: Recent Data and Implications for Practice' is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credits.
Each participant should claim only those hours of credit that have actually been spent in the educational activity. EBAC works according to the quality standards of the European Accreditation Council for Continuing Medical Education (EACCME), which is an institution of the European Union of Medical Specialists (UEMS).
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website.
Instructions to Participants
There is no fee for taking part in this online learning activity.
Activities are designed to be completed within 60 minutes and must be completed by the registered user. Physicians should only claim credits for time spent on the activity. To successfully earn credit, participants must complete the activity in full in the indicated time frame.
To complete the course and claim certification participants must:
- Read the PDF of the review article carefully and thoroughly, consider the learning objectives and implications, and then complete post-test questions at the end of the activity. Users must read and study the activity in its entirety before completing the post-test questions.
- Your results will be automatically saved and if the required pass score is achieved, you will be eligible to claim credit for the activity and receive a certificate of completion.
This programme is intended to educate:
- Cardiologists, heart failure specialists and other healthcare professionals who are engaged in the diagnosis and treatment of heart failure.
This review article endeavours to best address the following learning objectives:
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data.
- Differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF).
- Apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF.
- Assess the interrelationships linking diabetes, HF and CVD.
- Interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF.
- Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
1.00 European Board for Accreditation in Cardiology (EBAC)
- 1 EBAC
- Assess the current global burden of resistant hypertension
- Carry out appropriate assessments to identify resistant hypertension
- Identify patients most likely to benefit from RDN
- Recall the practical considerations for adopting RDN into routine practice
- Recall the latest data on RDN from recent clinical trials
- 1.00 EBAC
- Describe the evidence to support the use of renal denervation as a treatment modality in patients with resistant hypertension
- Understand renal denervation and how effective it is as a treatment option
- Identify patients with resistant hypertension suitable for renal denervation
- 1.00 EBAC
- Understand the SGLT2 inhibitor cardiovascular outcome trial (CVOT) data;
- differentiate the latest guideline updates for the treatment of T2D and their recommendations regarding the importance of considering comorbidities, including atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF);
- apply clinical and real-world evidence of the SGLT2 inhibitor class for use in prevention of hospitalisation in HF, as well as future ongoing studies in the treatment of HF;
- assess the interrelationships linking diabetes, HF and CVD;
- interpret the potential cardio-renal mechanisms of the SGLT2 inhibitor class in reducing the risk of CV, including HF. Evaluate emerging data of the treatment of HF with SGLT2 inhibitors in patients with or without T2DM.
- 1.00 (EBAC)
- Recall recent changes to guidelines following the publication of Phase III data with SGLT2 inhibitors in patients with HFrEF, with and without type 2 diabetes
- Describe the type and extent of clinical benefit observed when SGLT2 inhibitors are added to standard HF therapy in patients with HFrEF
- Assimilate prevailing hypotheses and insights from key thought leaders on optimal therapeutic sequencing of the ‘five pillars’ of HF therapy
- Apply newly gained knowledge on therapeutic sequencing to surrogate patient cases
- 0.25 AMA PRA Category 1 Credit™
- Recall the efficacy and safety of existing HCM treatments
- Summarize results from ongoing trials with experimental treatments for HFrEF and HCM